Abstract
During 6 months of treatment, we measured human immunodeficiency virus (HIV)-1 virus loads, CD4 T cell counts, and immune activation markers, in 111 HIV-1-infected patients with active tuberculosis (TB). The median virus load (baseline, 5.58 log(10) copies/mL) significantly increased at 1 month (5.71 log(10) copies/mL), then returned to near-baseline levels at 3 months (5.40 log(10) copies/mL) and at 6 months (5.36 log(10) copies/mL). In contrast, the median CD4 counts increased at 1 month (186/mm(3)), at 3 months (238/mm(3)), and at 6 months (239/mm(3)). CD4 counts and virus loads did not change during therapy. Expression of CD38 and HLA-DR remained high throughout treatment, whereas plasma levels of interleukin-6 decreased over time.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
AIDS-Related Opportunistic Infections / drug therapy
-
AIDS-Related Opportunistic Infections / immunology
-
AIDS-Related Opportunistic Infections / microbiology
-
Antitubercular Agents / pharmacology
-
Antitubercular Agents / therapeutic use*
-
CD4 Lymphocyte Count
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / immunology*
-
HIV Infections / complications*
-
HIV Infections / immunology
-
HIV Infections / virology
-
HIV-1 / drug effects
-
HIV-1 / genetics*
-
HIV-1 / isolation & purification*
-
Humans
-
Mycobacterium tuberculosis
-
RNA, Viral / analysis*
-
South Africa
-
Tuberculosis / complications
-
Tuberculosis / drug therapy*
-
Tuberculosis / immunology*
-
Tuberculosis / virology
-
Viral Load
Substances
-
Antitubercular Agents
-
RNA, Viral